BTIG reiterates Buy rating on Oruka Therapeutics, $151 price target

Piper Sandler reiterated an Overweight rating and $180.00 price target on Oruka Therapeutics (NASDAQ:ORKA), citing its drug pipeline. The stock is up 290% over 12 months, but currently trades at $79.69. Key catalysts include upcoming data for ORKA-001 and ORKA-002. H.C. Wainwright also reiterated a Buy rating with a $120 target.

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.

Oruka Therapeutics (ORKA) reported positive Week 28 results for ORKA-001 in a Phase 2a trial for plaque psoriasis, showing improved responses and a favorable safety profile. The stock is down 5.87% in pre-market trading.

Oruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.

Oruka Therapeutics (NASDAQ:ORKA) shares dropped 5% after reporting Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating plaque psoriasis. The trial showed a PASI 100 response rate of 71.4% and a PASI 90 rate of 87.3%. The company plans to release 52-week data in December 2026.

Oruka Therapeutics (NASDAQ:ORKA) shares fell 5% despite positive Week 28 trial data for its psoriasis treatment ORKA-001. The trial showed improved efficacy with PASI 100 response rates increasing to 71.4% and a favorable safety profile. The company plans to release 52-week data in 2026.